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Beta-secretase (BACE1) is the major enzyme participating in generation of toxic amyloid-beta (Aβ) peptides, identiﬁed in amyloid
plaques of Alzheimer’s disease (AD) brains. Its downregulation results in decreasing secretion of Aβ. Thus, BACE1 silencing by
RNAirepresentspossiblestrategyforantiamyloidtherapyinthetreatmentofAD.Inthisstudy,aseriesofnewlydesignedsequences
of synthetic and vector-encoded siRNAs (pSilencer, pcPURhU6, and lentivirus) were tested against overexpressed and endogenous
BACE1 in several cell lines and in adult neural progenitor cells, derived from rat hippocampus. SiRNAs active in human, mouse,
and rat cell models were shown to diminish the level of BACE1. In HCN A94 cells, two BACE1-speciﬁc siRNAs did not alter the
expression of genes of BACE2 and several selected genes involved in neurogenesis (Synapsin I, βIII-Tubulin, Calbidin, NeuroD1,
GluR2, CREB, MeCP2, PKR), however, remarkable lowering of SCG10 mRNA, coding protein of stathmin family, important in
the development of nervous system, was observed.
Copyright © 2009 Malgorzata Sierant et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Alzheimer’sdisease(AD)isaprogressivebraindiseaseaﬀect-
ing the elderly population, causing problems with memory,
thought, and behavior. Approximately 2–5% of AD cases are
familial (FAD), caused by autosomal dominant mutations
in amyloid precursor protein (APP) or the presenilin (PS1,
PS2) genes [1–3], while the majority of sporadic AD cases
are not associated with any known mutations. The hallmarks
of Alzheimer disease include intraneuronal neuroﬁbrillary
tangles, consisting of the hyperphosphorylated microtubule-
associated protein Tau and extracellular deposits of ﬁla-
ments of 42-residue amyloid β (Aβ)p e p t i d e[ 4, 5]. Aβ
deposits become increasingly ﬁbrilar and gradually acquire
the classical features of amyloid plaques [6]. Aβ is the
product of sequential cleavage of APP by β-a n dγ-secretases
[7, 8]. Nonharmful APP cellular processing by α-a n dγ-
secretases results in a short, highly soluble, nonamylogenic
p3 peptide [9]. In alternative amyloidogenic processing, APP
is hydrolyzed by β-a n dγ-secretases, and three possible pep-
tides (Aβ40, Aβ42, Aβ43) can be generated [10]. Variability
ofthecleavagesiteofγ-secretaseisassociatedwithmutations
in the PS1 and PS2 genes [11]. Aβ peptides are secreted
from the presynaptic terminal into the extracellular matrix,
where ﬁbrillary Aβ deposits are formed outside of neurons.
Some evidences suggestthat the Aβ aggregatesarethecritical
factor which triggers a complex pathological cascade leading
to neurodegeneration [12].Allstrategies tolowerbrainAβ42
levels should be therapeutically beneﬁcial in AD treatment.
Given that BACE1 is the initiating enzyme in Aβ generation,
it is considered a prime target for drug in AD for reducing
cerebral Aβ levels [13–15].
RNA interference (RNAi) is an eukaryotic regulatory
mechanism that uses double-stranded RNA (dsRNA) for
induction of posttranscriptional gene silencing by the
sequence-speciﬁc hydrolysis of homologous mRNA [16, 17].
RNAi has already been proposed for therapy of neurode-
generative diseases, including amyotrophic lateral sclerosis
(ALS) [18], spinocerebellar ataxia (SCA) [19], Hunting-
ton’s disease [20], and Alzheimer’s disease [21–23]. Using
lentiviral vectors expressing siRNAs targeting BACE1, Singer
et al. reduced the cleavage of APP at the beta site, lowered2 International Journal of Alzheimer’s Disease
amyloid burden, and achieved amelioration of dendritic and
synaptic pathology in the hippocampus of tested animals
[24]. Other BACE1 silencing studies, performed in vitro in
primaryneuronsderivedfromAPP-transgenicmice,resulted
in reduced production of APP fragments, CTFs and Aβ
[25].
The present studies concern optimization of RNAi for
eﬀective silencing of overexpressed and endogenous BACE1
protein in the human/mouse/rat cell cultures. For that pur-
pose we used original sequences of siRNAs coding synthetic
siRNA duplexes as well as shRNA-encoding plasmids and
lentiviral vector. Moreover, we analyzed the eﬀects of the
use of BACE1-speciﬁc siRNAs and, in consequence, BACE1
silencing on the expression of selected genes involved, for
example, in adult neurogenesis.
2.MaterialsandMethods
2.1. Preparation of siRNA Duplexes. The synthesis of RNA
oligonucleotides was performed according to the routine
phosphoramidite approach [26], using LCA CPG glass
support and commercially available nucleoside phospho-
ramidites (Glen Research). Oligonucleotide synthesis was
performed with an Applied Biosystems 394 instrument
under the conditions recommended by the manufacturer.
Assembly of siRNA duplexes was performed by mixing the
equimolar amounts of complementary sense and antisense
oligoribonucleotides in PBS buﬀer, heating at 96◦Cf o r
2 minutes, followed by slow (2 hours) cooling to room
temperature. The duplex structure of resulted siRNAs was
conﬁrmed in a 4% agarose gel.
2.2. Construction of Plasmid Vectors. Inserts for cloning
into the pcPURhU6 plasmid (iGene Therapeutics, Inc.,
Japan) were generated by annealing two complementary 62-
mer oligonucleotides containing (i) a 21 nucleotide (nt)
sense strand and 21nt antisense strand separated by loop,
(ii) a stretch of ﬁve thymidines as the Pol III promoter
termination signal, and (iii) both sides of the insert ﬂanked
by BspMI restriction site [27]. Additionally, the use of the
following loop sequences was explored: GTGTGCTGTCC,
TTCAAGAGA [28], CTTCCTGTCA, and TAGTGAAGC-
CACAGATGTA. Cloning into the pSilencer 2.0-U6 plasmid
(AmbionInc.,AppliedBiosystems)wasperformedaccording
to the manufacturer’s protocol.
2.3. Cell Line and Culture Conditions. HeLa (human,
cervical carcinoma) cells were cultured in RPMI 1640
medium (Gibco, BRL, Paisley) supplemented with 10%
heat-inactivated fetal bovine serum (FBS) (Gibco, BRL,
Paisley), 100U/mL penicillin, and 100μg/mL streptomycin
(Polfa) at 37◦C and 5% CO2. SH-SY5Y (human, Cau-
casian, bone marrow neuroblastoma) cells were cultured in
50% F12 Nutrient Mixture (HAM) medium (Gibco, BRL,
Paisley)/50% MEM (Gibco, BRL, Paisley), supplemented
with 15% FBS and antibiotics (100mg/mL streptomycin
and 100U/mL penicillin). HEK293 cells (human, embryonic
kidney) and M15 cells (mouse, mesonephric epithelium)
were cultured in Dulbecco’s MEM (Sigma-Aldrich Co., Saint
Louis, MO), supplemented with 10% FBS and antibiotics
at 37◦C and 5% CO2. Before transfection, the culture
medium was replaced with fresh medium, free of antibiotics.
Transfections were performed using Lipofectamine 2000
(Invitrogen) at a 2 : 1 ratio and appropriate siRNAs or
plasmids encoding shRNA were added. For dual ﬂuorescence
assay, HeLa cells were cotransfected with plasmid DNA
pDsRed2-N1, 15ng/well (BD Biosciences) and p-BACE-
GFP [29], 70ng/well, provided by Dr. Weihong Song (The
University of British Columbia, Vancouver, Canada), and
with siRNA (0.1–5nM ﬁnal concentrations) or plasmids
(pSilencer-shRNA/pcPURhU6-shRNA 30ng/well) dissolved
in OPTI-MEM medium (50μL/well, Gibco). The cells were
incubated for 5-6 hours and then medium with transfection
mixture was replaced with the fresh, culturing medium with
antibiotics. After 48-hour incubation at 37◦Ci na t m o s p h e r e
of5% CO2,thecellswerewashedthreetimeswithphosphate
saline buﬀer (PBS) and lysed overnight with mixture of
NP-40 buﬀer (150mM NaCl, 1% IGEPAL, 50mM Tris-
HCl (pH 7), 1mM PMSF and PBS (ratio 1 : 3) at 37◦C).
Cell lysates were used for ﬂuorescence determination by a
dual ﬂuorescence assay, as described previously [30]. Shortly,
ﬂuorescence values of enhanced green ﬂuorescent protein
(EGFP) and red ﬂuorescent protein (RFP) were measured
using a Synergy HT reader (BIO-TEK); data quantiﬁcation
was performed using KC4 software. Excitation and emission
wavelengths were as follows: GFP λEx = 485/20nm and
λEm = 528/20nm; RFP λEx = 530/25nm and λEm =
590/30nm. The siRNA activity was calculated as the ratio
o fG F Pt oR F Pﬂ u o r e s c e n c ev a l u e s ,a v e r a g e do v e re i g h t
repetitions. The relative level of ﬂuorescence (GFP/RFP)
in control cells (transfected with pBACE-GFP, pDsRed2-
N1 and control s-0 siRNA) was taken as the reference
(100%).
2.4. RT-PCR Analysis. HEK293, M15, SH-SY5Y cells were
transfected with plasmids encoding shRNA expression cas-
settes using Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s protocol. The cells were collected 36
hours after transfection, lysed with TriPure Isolation Reagent
(Roche Applied Science), and total RNA was extracted and
analyzed by RT-PCR. For a single reaction, 1μgo ft o t a lR N A
was used as a template. Primers of the following sequences:
for BACE1 (h/m/r): forward (633–652) TGTGGAGAT-
GGTGGACAACC, reverse (993-1012), ATCTCAGCATAG-
GCCAGCCC; for GAPDH (h): forward GAGTCAACG-
GATTTGGTCGT, reverse TTGATTTTGGAGGGATCTCG;
for GAPDH (m/r): forward GTGTGAACGGATTTGGCC-
GT, GAPDH (m) reverse TTGATGTTAGTGGGGTCTCG,
GAPDH (r) reverse TTGATGTTAGCGGGATCTCG were
synthesized in house. Commercially available primers were
used for RT-PCR ampliﬁcation of genes listed in Table 2.
The reverse transcription and PCR ampliﬁcation reactions
were performed using OneStep RT-PCR Kit (Qiagen). RT-
PCR reactions were performed according to the manu-
facturer’s protocol. Ampliﬁed samples were analyzed by
agarosegelelectrophoresisandquantiﬁedusingImageQuantInternational Journal of Alzheimer’s Disease 3
5.0 software. The level of GAPDH mRNA was used as
a reference.
2.5. Western Blot Analysis. Cell lysates obtained by TriPure
Isolation Reagent (Roche Applied Science) were used for
preparation of total protein fraction, according to manufac-
turer’s protocol. Protein samples (20μg for each lane) were
separated by 10% SDS-PAGE and semi-dry electroblotted
to Immobilon P PVDF membrane (Millipore Corp., Mass,
USA). Rabbit polyclonal anti-BACE1 (Santa Cruz Biotech-
nology Inc.) in dilution 1 : 300 and rabbit polyclonal anti-
β-actin (Abcam) in dilution 1 : 5000 were used as primary
antibodies.Membranewasincubatedwithdilutedantibodies
overnight at 4◦C. As secondary antibody, goat antirabbit IgG
conjugated to alkaline phosphatase (Zymed, San Francisco)
in dilution 1 : 5000 was used. Membrane was incubated one
houratroomtemperature.Boundantibodieswerevisualized
by reaction of alkaline phosphatase with chemiluminescence
substrate (Millipore Corp.) at the visualization system (G-
BOX, Syngene).
2.6. Lentivirus Vector Production. The packaging system
was described previously [31]. 293T cells were cultured
in 10cm dish in Iscove’s Modiﬁed Dulbecco’s Medium
(Gibco/Invitrogen), supplemented with 1% L-glutamine,
10% heat-inactivated FBS (Sigma) and 1% antibiotics
(Gibco/Invitrogen). The TUHC Pcsc-SP-PW-EGFP vector
[32]( 2 0 μg), coding for the shRNA sequence, and helper
vectors, pMDL (12μg), Rev (6μg), and VSVG (8μg), were
cotransfected into 293T cells using a calcium-phosphate
method [33, 34]. 48 and 72 hours after transfection, culture
medium was collected, pooled together, ﬁltered, and con-
centrated by ultracentrifugation. Lentivirus particles were
suspended in PBS and stored at 4◦C until use. Virus titers
were determined by transduction of 293T cells and enhanced
GFP expression visualization using ﬂuorescence microscopy.
2.7.TransductionofHCNA94Cells. HCNA94cells(adultrat
hippocampal neural stem cells) were cultured as described
[35]. The day before transduction, cells were passaged into 6
well plates. Then, the cells were transduced with appropriate
recombinant lentiviruses: Lv-si-5, Lv-si-6, and control Lv-
EGFP. After infection, the HCN A94 cells were cultured in
conditionsspeciﬁcforneuronaldiﬀerentiation:inF12media
containing 1% N-2 Supplement (Gibco BRL, Paisley) with
1μM retinoic acid (RA) and 5μM forskolin (Sigma). Four
days after infection, level of mRNA of the screened proteins
were determined by RT-PCR.
3. Results
3.1. Selection of Active siRNA/shRNA Sequences in Dual
Fluorescence Assay (DFA). Several target sites in human/
mouse/rat (h/m/r) BACE1 genes were selected for siRNA
duplexes using available tools [36–39]. The siRNA duplexes
used had the typical structure of 19-base pairs (bp) fully
complementary duplex with 2-nucleotide (nt) overhangs at
each 3  end, typically two thymidine units (Table 1). All
RNA strands were synthesized in house and their structures
and purity were uniformly conﬁrmed by MALDI-TOF MS
and PAGE electrophoresis, respectively, (data not shown).
The shRNA encoding sequences were designed to express
RNA transcripts with a hairpin structure of a 19-bp stem
with a 9-nt loop: TTCAAGAGA (pSilencer 2.0-U6) [28],
or a 21-bp stem with an 11-nt loop: GTGTGCTGTCC
(pcPURhU6) [27]. To investigate the silencing activity of
siRNA duplexes or shRNA-expressing vectors we optimized
a dual ﬂuorescence reporter system (DFA) [30, 40]. The
system is based on measurement of the relative ﬂuorescence
intensity of enhanced green ﬂuorescent protein (EGFP,
expressed from fusion p-BACE-GFP [29] plasmid) and coral
(Discosoma spp.) derived red ﬂuorescent protein (RFP),
expressedinHeLacellsfromexogenouslydeliveredplasmids.
Localization of ﬂuorescent proteins is shown in Figure 1(a),
andinterestinglyBACE1-EGFPfusionproteinlocalizesinthe
cytoplasmatic membranes, probably in the Golgi apparatus
and/or ER compartments [41], while RFP protein is present
in the nucleus and cytoplasm with no localization in the
membrane. All duplexes used in the experiments mediated
the human target gene silencing to varying extent (see
Table 1), depending on the siRNA concentration and target
site. Variability of siRNA potency is most likely the result of
changed thermodynamic properties of the 5 -a n d3  -ends of
the duplexes as well as secondary structure of target mRNA
[30]. Representative microscopic images of DFA control cells
(transfected with pDsRed2-N1 and p-BACE-GFP plasmids)
and cells additionally transfected with si-2 and si-4 duplexes
are shown at Figure 1(b).
3.2.ActivityofsiRNA/shRNAConstructsAgainstEndogenously
Expressed BACE1. Silencing activities of siRNAs or shRNA-
encoded plasmids directed toward endogenous BACE1
mRNA were screened in human (HEK293 and SH-SY5Y)
and mouse (M15) cell lines by semiquantitative RT-PCR
and by Western blot analysis. In SH-SY5Y cells, the most
active was si-4 duplex which lowered BACE1 mRNA level
up to 34% (100% value consists of BACE1 expression in
control sample without silencing) (see Table 1). Low activity
of siRNA in SH-SY5Y neuroblastoma cell line was probably
caused by lower transfection eﬃciency of these cells as
compared to HeLa cells, in which screened duplexes si-
2–si-4 were much more active. Fluorescence of GFP or
RFP expressed from pGFP-BACE or pDsRed2-N1 plasmids,
respectively, was ca. 10–20 times higher in HeLa cells than
in SH-SY5Y cells transfected in standard conditions (using
lipofectamine at a 2 : 1 ratio) (see Figure 2). The pcPURhU6
si-5 vector (sequence corresponding to si-5a), speciﬁc for
the human BACE1 gene, was the most potent inhibitor in
HEK293 cells (32% of expression of the control sample).
Additionally, pcPURhU6 si-5b, speciﬁc for mouse and rat
BACE1 mRNA,also revealed high silencing eﬃciency in M15
mouse cells (30% of expression level of the control sample).
The second plasmid construct, pcPURhU6 si-6 (sequence
corresponding to si-6), speciﬁc for the h/m/r BACE1 gene,4 International Journal of Alzheimer’s Disease
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Figure 1: Expression of pBACE-GFP/pDsRed2-N1 plasmids in HeLa cells (a) and silencing eﬀect of selected siRNAs in these cells (b).
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Figure 2: Comparison of transfection eﬃciency of pGFP-BACE or pDsRed2-N1 plasmids in HeLa and SH-SY5Y cells.
resulted in BACE1 expression of 51% in HEK293 cells and
71% in M15 cells.
3.3. Optimizing the Loop Length of shRNA Constructs. The
loop structure has a signiﬁcant impact on export of pre-
miRNA or shRNA from nucleus [42] and their silencing eﬃ-
ciency was proven to be the most eﬃcient with loops ranging
from 9 to 19nt [27, 28, 36]. We designed and cloned into the
pcPURhU6 vector the hairpin-type RNAs with si-6 sequence
(pcPURhU6 si-6) with the 19-21 base pair (bp) stems and
with various loops: (1) pcPURhU6 si-6 (21bp)-miR26, (2)
si-6 (19bp) with 9-nt UUCAAGAGA loop [28], (3) si-6
(21bp) with 9-nt UUCAAGAGA loop, (4) si-6 (21bp) with
10-nt CUUCCUGUCA (loop from miRNA23), and (5) si-
6 (21bp) with 19-nt UAGUGAAGCCACAGAUGUA (loop
from miRNA30) (see Figure 3). All ﬁve plasmids were tested
inHEK293cellsandthemostactivewastheconstruct1caus-
ing 50% lowering of BACE1 mRNA. Constructs 4 and 5 withInternational Journal of Alzheimer’s Disease 5
Table 1: SiRNA sequences, target sites in human, mouse, and rat mRNA of BACE1 and silencing activity of used siRNA- and shRNA-coded
plasmids (presented as % of BACE1 gene expression).
Target gene
(nt numbers)
%o f
BACE-GFP
expression in
DFA by
siRNA
(5/1/0.1nM)∗
%o f
BACE-GFP
expression in
DFA by
shRNA in
plasmid∗#
%o fB A C E 1
expression in
SH-SY5Y (human)
cells by siRNA
(RT-PCR/western
blot)∗&
%o fB A C E 1
expression in HEK293
(human)/M15 mice
cells by shRNA in
pcPURhU6@
(RT-PCR)
Sequence:
No 5 -sense strand-3 
3 -antisense strand-5 
si-0
5 -AAUCAGAUUGAACCUUCAUTT-3  non-silencing
control siRNA 100 100 86 100
3 -TTUUAGUCUAACUUGGAAGUA-5 
si-1
5 -UACAGGCAGCAGUAACUUUTT-3  h (733–753)
m (-)
r (-)
27/31/58 40
(pSilencer) nd nd
3 -TTAUGUCCGUCGUCAUUGAAA-5 
si-2
5 -AGACGCUCAACAUCCUGGUTT-3  h (710–730)
m (-)
r (-)
6/22/76 nd 61/60 nd
3 -TTUCUGCGAGUUGUAGGACCA-5 
si-3
5 -GAAUCAGACAAGUUCUUCAUC-3  h (946–966)
m (-)
r (-)
0.0/1.1/16 5 (pSilencer) 55/61 nd
3 -GACUUAGUCUGUUCAAGAAGU-5 
si-4
5 -AAUCAGACAAGUUCUUCAUTT-3  h (947-967)
m (-)
r (-)
0.0/1.7/15 11
(pSilencer) 34/61 nd
3 - TTUUAGUCUGUUCAAGAAGUA-5 
si-5a
5 -AUCAGACAAGUUCUUCAUCAA-3  h (948–968)
m (-)
r (-)
28/35/60 12
(pcPURhU6) nd 32/92
3 -GAUAGUCUGUUCAAGAAGUAG-5 
si-5b
5 -AUCGGACAAGUUCUUCAUCAA-3  h (-)
m (920–940)
r (920–940)
nd nd nd 52/30
3 -GAUAGCCUGUUCAAGAAGUAG-5 
si-6
5 -GACUGUGGCUACAACAUUCCA-3  h (1777–1797)
m (1751–1771)
r (1751–1771)
1.3/8/45 20
(pcPURhU6) nd 51/71
3 -UUCUGACACCGAUGUUGUAAG-5 
∗ : GFP/RFP relative ﬂuorescence of the control, HeLa cells transfected with control nonsilencing siRNA (si-0) or pSilencer-Neg plasmid/Lipofectamine 2000
were taken as a reference nonsilenced value of 100%;
#: plasmid DNA 30ng/well (96-well plate);
&: 100nM siRNA;
@: plasmid DNA 2μg/well (6-well plate);
Nd: not determined.
miRNA-origin loops miRNA23 and miRNA30, respectively,
demonstrated moderate silencing activity, lowering BACE1
mRNA by 27% and 38%, respectively.
3.4. BACE1 Silencing in HCN A94 Progenitor Cells. In
order to validate the eﬀects of shRNAs on BACE1 gene
expression in rat cells model, the lentiviral vectors were
constructed and used for the Lv-si-5 and Lv-si-6 lentiviruses
production. The high titer lentiviruses Lv-si-5 and Lv-si-6
wereusedfortransductionofadulthippocampalneuralstem
cells HCN A94. Both vectors caused signiﬁcant reduction
in BACE1 mRNA (>75%) in comparison to the level of
mRNA expressed by control cells (Figure 4). In search
for additional functions of BACE1 or products of BACE1
proteolytic activity, we analyzed mRNA levels of several
genes involved in adult neurogenesis (listed in Table 2).
Their list consists of a transcription factor Sox-2 (essential
for maintaining progenitor cells in the undiﬀerentiated
stage), transcription factors Neurogenin 1–3 and NeuroD1,
NRSF/REST (expressed during neuronal diﬀerentiation and
responsible for activation of the expression of neuronal
genes), Synapsin I, NaChII, GluR2, βIII-Tubulin, Calbidin,
BDNF, and SCG10. Additionally, we assessed expression
of GFAP, indicative of astrocytes; MBP, speciﬁc for oligo-
dendrocytes; and genes of CREB, MeCP2, APP, BACE2,
PKR, and GAPDH. Selected data are shown in Figure 4.
In most cases we did not ﬁnd any inﬂuence of BACE1-
speciﬁc siRNAs on the mRNA level of the above-mentioned
genes. Interestingly, we found correlation between BACE1
and SCG10 gene expression, as BACE1 inhibition by Lv-si-
5 and Lv-si-6 resulted in simultaneous downregulation of6 International Journal of Alzheimer’s Disease
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Figure 3: Optimizing of the loop sequence of si-6-based shRNA in HEK293 cells, as evaluated by RT-PCR: (1) pcPURhU6 si-6 (21bp)-
miR26, (2) si-6 (19bp) with 9-nt UUCAAGAGA loop, (3) si-6 (21bp) with 9-nt UUCAAGAGA loop, (4) si-6 (21bp) with 10-nt
CUUCCUGUCA (loop from miRNA23), and (5) si-6 (21bp) with 19-nt UAGUGAAGCCACAGAUGUA (loop from miRNA30).
SCG10 (Figure 4, Table 2). Moreover, during neurogenesis in
conditions favouring the diﬀerentiation of progenitor cells
the level of BACE1 expression was increasing over the four
days of the experiment (data not shown).
4. Discussion
Many Alzheimer’s disease treatments are aimed at blocking
theformationofpathogenicamyloid-βpeptides.Bothβ-and
γ-secretases, due to their crucial role in the secretion of Aβ,
aresupposedtobeusefultherapeutictargets.Successfulinhi-
bition of these enzymes may reduce the burden of amyloid-
β-peptide in AD patients’ brains, which may slow down
the neurodegeneration. Inhibition of γ-secretase activity can
e v o k es e v e r es i d ee ﬀects, because this protease is involved in
processing of other important substrates, including Notch
receptor and cell surface proteins type I [43, 44]. Therefore,
BACE1, being a major β-secretase participating in the
toxic Aβ generation in the brain, is a primary therapeutic
target. Multiple strategies have been used to inhibit BACE1
gene expression, including antisense oligonucleotides and
catalytic nucleic acids [21, 25, 45–48]. In the present
studies, we used the RNAi technology for selective inhibition
of BACE1 gene expression. It was already demonstrated
that silencing of BACE1 decreases the amount of secreted
Aβ peptides [21, 24, 25, 47], therefore the main goal of
these studies was to select siRNAs that are able to reduce
speciﬁcally BACE1 expression in the designed experimental
system. Several siRNA sequences directed toward human,
mouse, and rat BACE1 mRNA were originally designed and
their functionality against overexpressed and endogenous
BACE1 was evaluated. The experiments were performed in
HEK293 and SH-SY5Y human and M15 mouse cell lines
as well as in HCN A94 rat cells, where a lentiviral vector
expressing active shRNA was applied. As determined in the
BACE-GFP/RFPdualﬂuorescenceassay,themostactivewere
si-3 and si-4 constructs, which at 100pM concentration
reduced the level of BACE-GFP mRNA by ca. 85%. These
two siRNAs were the most active in the same system when
introduced into pSilencer plasmid (5 and 11% of BACE1
expression, resp., in comparison to the control sample).
Interestingly, two other siRNAs, si-5a and si-6, cloned into
pcPURhU6 plasmid, silenced BACE1 in more than 80%, and
may oﬀer a good model system for further investigations
with the use of plasmid-coded siRNA. Synthetic siRNAs,
si-2, si-3, and si-4, transfected into human SH-SY5Y cells,
reduced BACE1 mRNA and protein level to the lower extent
than it was seen in DFA experiments performed in HeLa
cells. Although SH-SY5Y neuroblastoma cells endogenously
e x p r e s sh i g hl e v e lo fβ-secretase and are often used in
studies on neurodegeneration [49], their low transfection
eﬃciency using conventional approach is the most limiting
feature. 5-Fold lower transfection eﬃciency of pEGFP-C1International Journal of Alzheimer’s Disease 7
Table 2: List of genes selected for expression level evaluation in HCN A94 cells transfected with BACE1-speciﬁc si-5b and si-6, coded in
lentivirus vector.
No Protein Name/Function
%o f
silencing
with Lv-si-8
%o f
silencing
with Lv-si-9
1 BACE1 Beta-site APP cleaving enzyme 1 >70 >75
2 BACE2 Beta-site APP cleaving enzyme 2 ——
3 SCG10 Superior cervical ganglion-10 70 70
4 NeuroD1 Neurogenic diﬀerentiation 1 ——
5 GluR2 Glutamate receptor 2 ——
6 CREB cAMP responsive element binding protein 1 ——
7 MeCP2 Methyl CpG binding protein 2 ——
8 Synapsin 1 Protein involved in the regulation of neurotransmitter release at synapses ——
9 PKR Double stranded RNA-dependent protein kinase ——
10 GAPDH Glyceraldehyde-3-phosphate dehydrogenase ——
11 Sox-2 SRY (sex determining region Y)-box 2 ——
12 NRSF/REST Neural restrictive silencing factor ——
13 NaChII Sodium channel, voltage-gated, type II ——
14 βIII-Tubulin Neuro-speciﬁc tubulin, microtubules component ——
15 Calbidin Vitamin D-dependent calcium-binding protein ——
16 BDNF Brain-derived neurotrophic factor ——
17 GFAP Glial ﬁbrillary acidic protein, protein speciﬁc for astrocytes in CNS ——
18 APP Amyloid Precursor Protein ——
19 Neurogenin 1–3 Neurogenins, family of the transcription factors involved in the neuronal diﬀerentiation ——
BACE1
C
o
n
t
r
o
l
L
v
-
s
i
-
8
L
v
-
s
i
-
9
BACE2
SCG10
NeuroD1
GluR2
CREB
MeCP2
Synapsin
PKR
NRSF/REST
GAPDH
Figure 4: Inﬂuence of Lv-si-5b and Lv-si-6 and BACE1 silencing
on expression of selected genes in HCN A94 cells, as determined by
RT-PCR.
plasmid into SH-SY5Y cells in comparison to HeLa cells
was observed with the use of conventional polycationic
transfecting agents as well as with the more sophisticated gas
plasma transfection methodology [50]. In our experiments,
transfection of plasmid DNA, assessed by the extent of
expression of pGFP-BACE or pDsRed2-N1 plasmids in SH-
SY5Y cells, reached the level of only 10 –20% of that in HeLa
cells (Figure 2).
SiRNA si-5 was used in two forms—si-5a speciﬁc
for human BACE1 mRNA and si-5b, varying with one
nucleotide, speciﬁc for mouse and rat homologs. Both
these siRNAs were rather selective toward cognate genes,
as it is seen from experiments in HEK293 and M15 cells
with siRNAs coded in pcPURhU6 plasmid (Table 1, the last
column). Thus, fully complementary si-5a caused selective
silencing of human BACE1 (32% of BACE1 expression) but
being by one nucleotide mismatched (U→C) with mouse
BACE1 mRNA, it was almost inactive toward this gene (92%
of BACE1 expression). In contrary, the duplex si-5b, fully
complementary to mouse BACE1 mRNA, was more eﬃcient
in mouse M15 cells than in HEK293 human cells. Such high
speciﬁcity of siRNA with mutation at the position 16 of the
antisense strand (counting from the 5 -end of this strand)
was previously reported by Schwarz et al. for two alleles of
the same gene of SOD1 [51].
To improve the knockdown eﬃciency of our con-
structs, we designed and cloned hairpin-type RNAs with
the same stem sequence, but with various loops, derived8 International Journal of Alzheimer’s Disease
from miRNAs: 23, 26b, or 30. All variants showed suppres-
sive activity, but the most potent was the construct with
the 21bp stem and 11-nt loop from the microRNA 26b
(50% expression of target BACE1). Moreover, the eﬃcacy
of constructs with the same loop sequence did not depend
on the length of stem (19-bp or 21-bp) (see the activity of
constructs2and3,Figure 3).Finally,activesiRNAsequences,
si-5b and si-6, were cloned into lentiviral vector (TUHC
pCSC-SP-PW-EGFP)andusedtosilencethetargetproteinin
rat adult neural progenitor cells HCN A94. Both lentivirus-
c o d e ds i R N A sw e r ev e r ye ﬃcient in BACE1 silencing in
HCN A94 cells, allowing to demonstrate that si-5b and
si-6 duplexes, complementary to human, mouse, and rat
mRNA target sites, can be simultaneously used as inhibitors
of BACE1 gene expression in human, mouse, and rat cells,
although with various eﬃciency in particular cells.
We asked a question, whether the activity of BACE1-
speciﬁc siRNAs, and in consequence silencing of BACE1
protein, inﬂuence the proﬁle of expression of other genes.
Such nonspeciﬁc “oﬀ-target” eﬀects are observed when
target-speciﬁc siRNA molecules are used at high molar
concentrations (>100nM) [52, 53]. Subsequent analysis of
mRNA levels of several genes involved in neurogenesis
showed that screened siRNAs and BACE1 silencing did
not aﬀect the expression of most of selected genes (see
Table 2). Unexpectedly, we observed downregulation of
SCG10 expression. NCBI/BLAST analysis has shown no
signiﬁcant similarity between SCG10 and BACE1 sequences.
Therefore, our observation suggests the presence of a reg-
ulatory pathway for SCG10 expression involving BACE1 or
products of its proteolytic activity, although this hypothesis
requires additional studies. SCG10 is a neuron-speciﬁc
member of the stathmin family of microtubule regulatory
proteins. Like stathmin, it can bind to soluble tubulin and
depolymerize microtubules in neurons. Because this protein
has restricted localization in neurons, expression of SCG10
gene is tightly regulated, mainly by NRSF/REST transcrip-
tion factor [54]. Other regulators or modulators of SCG10
expression remain unknown. It would be interesting to
explain the potential metabolic pathway between β-secretase
and SCG10 and these studies are currently in progress.
The SCG10 downregulation observed during RNAi-induced
silencing of BACE1 may constitute important limitation of
therapeutic application of this antiamyloid gene therapy,
especially because increased expression of SCG10 is observed
in the cortical and hippocampal regions of brain after the
neuronal lesions [55].
In summary, we demonstrate high silencing activity of
synthetic siRNAs and viral vectors-encoded shRNAs against
overexpressed and endogenous BACE1. This process is fairly
selective as expression of majority of screened genes involved
inneurogenesisisnotaﬀectedbyBACE1-speciﬁcsiRNAsnor
by BACE1 level reduction.
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